Havana, Mar 14 (Prensa Latina) Soberana 02, the Cuban anti-Covid-19 vaccine candidate, beings its phase III clinical trials in Iran, with the arrival in that country of 100,000 doses, announced the famous business group BioCubaFarma of the largest of the Antilles.
As part of the collaboration with other countries in the development of vaccines against COVID19, 100,000 doses of Soberana02 were sent to the Pasteur Institute of Iran, which will be used in clinical trials in that country, BioCubaFarma noted.
Since December, the director of the Finlay Vaccine Institute (IFV), project leader, Vicente Vérez, told Prensa Latina that the last stage of the study of this project was also planned to be carried out in other nations.
With this objective in mind, at the beginning of the year, said institution signed a collaboration agreement with the Pasteur Institute of Iran.
In its official Twitter account, the Cuban entity explained that ‘this synergy would allow faster progress in immunization in both countries against the SARS-CoV-2 virus, which causes Covid-19.
For his part, the spokesman for the Iranian Food and Medicine Organization, KianushYahanpur, reported that the arrival of the injectable is intended to carry out joint clinical studies of that period.
In the event that the final efficacy results of Soberana 02 are confirmed, mass production of this product will be launched in both Iran and the Caribbean country, Yahanpur announced.
For this, he said, the technical methodology will be transferred to Tehran through such collaboration.
Last Monday, Cuba began phase III of clinical trials of Soberana 02 in eight municipalities of Havana with more than 44 thousand volunteers.
In this way, he became the first candidate from Latin America to reach that stage.
Among the objectives of the study are to evaluate the efficacy of the product to prevent symptomatic disease and, in addition, that the individual does not go to serious forms of the disease or dies.
Cuba is developing four other vaccine candidates: Soberana 01, Soberana Plus, Mambisa and Abdala. The latter from the Center for Genetic Engineering and Biotechnology.
"An Island on a Continent" 